NPM1 and acute myeloid leukemia: Interestingly, PRDM16Low was associated with favorable survival (median OS; 65.3 vs 10.4 months; p = 0.0065; Fig. 2C and D) in a subgroup analysis within the NPM1/FLT3-ITD double-mutant genotype (n = 200), compared to AML patients with PRDM16Int/High.